Healthcare cost and policy

Medicare drug price negotiation: the $6 billion question

Originally posted by

Medicare Drug Price Negotiations: A $6 Billion Question

The Biden administration recently announced that Medicare is expected to save $6 billion from the first round of price negotiations on 10 widely used drugs. This is huge, with seniors projected to save $1.5 billion on out-of-pocket costs starting in 2026.

However, this raises an important question: Will the overall economy truly save $6 billion, or will these costs be shifted elsewhere?

While the savings are a relief for seniors and taxpayers, drugmakers argue that the negotiation process is unconstitutional and could impact the pharmaceutical industry. What are your thoughts on the broader economic implications of these savings?

https://lnkd.in/gUFadabF

Originally posted on LinkedIn, where the discussion and source links live in the comments.

About the author

Chris Vanderwolk is Director of Compliance and Innovation at OneDigital | Kistler Tiffany Benefits General Agency, where he helps brokers and employers navigate the regulatory complexity of employee benefits. An ERISA attorney with more than 19 years in the benefits industry, he specializes in translating what the law actually requires into language people can use.

All writing